MedTrace Logo

Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography

NCT06278246 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2025-03-28

No results posted yet for this study

Summary

Within the schizophrenia population, there are individuals that respond to first-line antipsychotic treatments while others do not. The availability of muscarinic M4 subtype receptors (M4R) may play a role as to whether a person with schizophrenia is responsive to first-line antipsychotics or not. The goal of this observational study is to compare the availability of M4R in antipsychotic-free patients with schizophrenia and matched healthy controls. In addition, M4R availability in schizophrenia patients will be examined in relation to response to first line antipsychotics and clinical and cognitive measures. This study may help better understand antipsychotic resistance in schizophrenia and lead to the development of new treatment options, particularly for cognitive deficits and negative symptoms.

Conditions

Interventions

RADIATION

PET Scan

PET scan using the novel \[11C\]MK-6884 tracer to measure M4R during the antipsychotic-free state

Sponsors & Collaborators

  • Centre for Addiction and Mental Health

    lead OTHER

Principal Investigators

  • Ariel Graff, MD, PhD · Centre for Addiction and Mental Health

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-11
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06278246 on ClinicalTrials.gov